Navigation Links
Australian Patent Issued to CreAgri® for Ultraviolet Radiation (UVR) Protection by its Hydroxytyrosol-Based Formulations

HAYWARD, Calif., Aug. 26 /PRNewswire/ -- CreAgri, Inc.® announced today that the company has received a Patent by the Australian Patent Office, Patent Number 2003249719, which covers the protective effects provided by Hydroxytyrosol against skin damage caused by UV exposure.

The patent claims are very broad and include formulations containing the two most important olive polyphenols, Hydroxytyrosol and Oleuropein, whether delivered orally and/or in conjunction with topical applications.

"We believe that products containing Hydroxytyrosol, whether orally ingested and/or topically applied, will provide an effective protection against the edema and erythema produced by excessive sun exposure, especially in areas of the world where skin problems are aggravated by the depletion of the ozone layer like Australia," declares Dr. Roberto Crea, CreAgri's President and CEO and author of the patent. "Increased exposure to UV rays in humans and animals has been linked to many severe diseases, including melanoma, carcinoma and immune diseases," adds Dr. Crea.

"The scientifically proven activities of Hydroxytyrosol in decreasing levels of TNF-alpha and in scavenging free radical molecules may partially explain the protective effect on skin," adds Dr. Cathy Bitler, CreAgri CSO and first author of a peer-reviewed publication that describes the anti-inflammatory properties of HT.

Together with its immune-balancing activity, Hydroxytyrosol, provided in high concentration by CreAgri's proprietary formulation, Hidrox®, directly blocks the effects of UV-induced free radicals in skin and other tissues of the body, and thereby, decreasing the concomitant inflammation.

Hidrox® provides the highest amount of Hydroxytyrosol in its natural environment, as in the juice of olives. Hidrox® is the only Hydroxytyrosol–rich formulation in the world produced from organic olives that does not involve extraction by solvents or other chemical separations.

The product is certified Generally Recognized as Safe (GRAS) and has been successfully tested in several human trials in many countries of the world, including USA, Japan and Malaysia.

About CreAgri® (

CreAgri® is the world's leading developer and supplier of antioxidant olive polyphenols for functional foods and beverages, dietary supplements, cosmetics and skincare applications. For ten years, CreAgri® has been the research leader in providing consumers and industry with the highest quality free radical-scavenging olive polyphenols. CreAgri's®' internationally acclaimed product, HIDROX®, has been formulated for dietary supplements, cosmetics, and skin-care products; all featuring the antioxidant power of natural HYDROXYTYROSOL, the olive active bio-phenol with the highest free-radical scavenging activity of any known natural or synthetic antioxidants.


HIDROX® is CreAgri's® trademarked hydroxytyrosol formulation, a powerful polyphenol scientifically recognized for its anti-oxidant properties and efficacy in heart and joint health. HIDROX® is the only olive polyphenols formulation with GRAS certification, meaning that it has been subjected to the most comprehensive set of safety and clinical efficacy tests. HIDROX® is also covered by the largest number of international patents for applications that include hydroxytyrosol and olive polyphenols. It is available in three forms to fulfill a variety of applications: HIDROX® 12% Total Polyphenols (6% hydroxytyrosol) freeze dried powder, HIDROX® 6% Total Polyphenols (3% hydroxytyrosol) powder and HIDROX®0.5% Total Polyphenols liquid.  All products are available in volumes ranging from kilograms to metric tons and can be ordered directly from CreAgri®.

About Skin Cancer

Each year more than 1,200 Australians die from skin cancer and in the US, more than 1 million new cases of skin cancer are diagnosed each year. (1) The American Cancer Society estimates that there are currently 480,000 cases of melanoma in the US alone today and that there are 7,700 deaths per year from the disease. Melanoma incidence rates in Australia and New Zealand are around four times as high as those found in Canada, the US and the UK. (2) Overall, melanoma is the fourth most common cancer in Australia. (3)

For more information about CreAgri®, visit For media related inquiries, contact Paolo Pontoniere (510) 732-6478 ext. 107, or Gillian Christie at Christie Communications, (805) 969-3744 or

(1), American Cancer Society's 2007 Facts & Figures

(2) Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia 2001. 2004.

(3) Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR). Cancer in Australia: an overview, 2006. Cancer Series Number 37. Canberra: AIHW, 2007.

SOURCE CreAgri, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
2. SenesTech, Inc. Commences Product Registration Process With Australian Government
3. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
4. The Australian Research Council Selects Scopus for the Evaluation of the Australian Research Landscape
5. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
6. Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight
9. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
10. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
(Date:10/13/2015)... PARK, N.J. and SAN DIEGO ... (BASF) and Mast Therapeutics, Inc. have agreed to collaborate ...  Currently, excipient-grade poloxamer 188 NF, marketed by BASF under ... used in a variety of pharmaceutical and biological applications, ... Poloxamer 188 is the starting material for Mast,s lead ...
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... a non-binding Letter of Intent (LOI) with MediTemp Ltd. (MediTemp) ... a proprietary cooling technology designed to improve sperm quality in ... United States and three million men in ... 44 diagnosed as infertile.  For 42% of those men, the ...
(Date:10/13/2015)... ... , ... Proove Biosciences, a commercial and research leader ... Keck Medicine of the University of Southern California (USC) Pain Center to ... Research Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one ...
(Date:10/12/2015)... ... October 12, 2015 , ... Spirax Sarco, the leader in products ... CSM-C 600 compact clean steam generator . This unit is a skid ... of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 generator can produce up ...
Breaking Biology Technology:
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/29/2015)... , Sept. 29, 2015 News ... productivity while also saving energy , Minimized design ... Low Power Active Mode and embedded Fujitsu PalmSecure authentication ... Fujitsu today shows that good things come ... refreshed models to its enterprise desktop and mobile portfolio. ...
(Date:9/28/2015)... , September 28, 2015 ... expected to reach USD 12.03 billion by 2020, growing ... Technological advancements such as Backside Illumination (BSI) technique to ... over the forecast period.      (Logo: ... of the chip to reduce loss and, thus, reduce ...
Breaking Biology News(10 mins):